US FDA Neurology Drugs Program Gains Boost In FY 2023 Funding Bill Amid Calls To Clarify Development Policies
Executive Summary
US FDA gains a nearly 7% increase in non-user fee funding, some of which will go for neurology drug guidance.
You may also be interested in...
Gene Therapy Sponsors Claim US FDA ‘Processing Error’ Could Cause Delays
Office of Therapeutic Products Director Nicole Verdun says the problem is uncommon and sometimes relates to missing manufacturing information.
Congress Gives US FDA Austere Budget But Seeks Boosts On Inspections, IT, And ALS Activities
The minor cut would be masked by user fee revenue increases, but still would be the first time in at least a decade that agency's budget authority has dropped.
Will Califf’s Attention To Foods Come At Expense Of US FDA’s Drugs Program?
FDA Commissioner Robert Califf says the medical product programs have received a lot of attention and now it’s the food program’s turn.